Abstract:The developmental process of central nervous system (CNS) myelin sheath formation is characterized by well-coordinated cellular activities ultimately ensuring rapid and synchronized neural communication. During this process, myelinating CNS cells, namely oligodendrocytes (OLGs), undergo distinct steps of differentiation, whereby the progression of earlier maturation stages of OLGs represents a critical step toward the timely establishment of myelinated axonal circuits. Given the complexity of functional integration, it is not surprising that OLG maturation is controlled by a yet fully to be defined set of both negative and positive modulators. In this context, we provide here first evidence for a role of lysophosphatidic acid (LPA) signaling via the G protein-coupled receptor LPA6 as a negative modulatory regulator of myelination-associated gene expression in OLGs. More specifically, the cell surface accessibility of LPA6 was found to be restricted to the earlier maturation stages of differentiating OLGs, and OLG maturation was found to occur precociously in Lpar6 knockout mice. To further substantiate these findings, a novel small molecule ligand with selectivity for preferentially LPA6 and LPA6 agonist characteristics was functionally characterized in vitro in primary cultures of rat OLGs and in vivo in the developing zebrafish. Utilizing this approach, a negative modulatory role of LPA6 signaling in OLG maturation could be corroborated. During development, such a functional role of LPA6 signaling likely serves to ensure timely coordination of circuit formation and myelination. Under pathological conditions as seen in the major human demyelinating disease multiple sclerosis (MS), however, persistent LPA6 expression and signaling in OLGs can be seen as an inhibitor of myelin repair. Thus, it is of interest that LPA6 protein levels appear elevated in MS brain samples, thereby suggesting that LPA6 signaling may represent a potential new druggable pathway suitable to promote myelin repair in MS.

Lysophospholipid receptors in drug discovery

Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain

Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease

Elucidating the Binding Mechanism of LPA Species and Analogs in an LPA4 Receptor Homology Model

Lysophospholipid receptors in neurodegeneration and neuroprotection

Intercellular Lipid Mediators and GPCR Drug Discovery

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects

Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate

Lysophosphatidic Acid Signaling Via LPA6: A Negative Modulator of Developmental Oligodendrocyte Maturation

Synthesis and Biological Evaluation of Lysophosphatidic Acid Analogues Using Conformational Restriction and Bioisosteric Replacement Strategies

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Toward the Three-Dimensional Structure and Lysophosphatidic Acid Binding Characteristics of the LPA(4)/p2y(9)/GPR23 Receptor: a Homology Modeling Study.

Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA1 antagonist for the treatment of systemic sclerosis

Sphingosine-1-phosphate: a Potential Therapeutic Target for Rheumatoid Arthritis

Targeting the LPA1 Signaling Pathway for Fibrosis Therapy: a Patent Review (2010-Present)

Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Structural basis for ligand recognition and signaling of the lysophosphatidylserine receptors GPR34 and GPR174

Structural mechanisms of potent lysophosphatidic acid receptor 1 activation by nonlipid basic agonists

Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.